Akers Biosciences Inc (AKER)
50
  • CONTENT
  • SOURCES
Aker : Carbon Capture AS and Aker Offshore Wind Holding AS – Private Placements Successfully Placed | MarketScreener
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER… | August 14, 2020
Why Akers Biosciences Is Trading Higher Today
Akers Biosciences Inc (NASDAQ: AKER ) shares are trading higher … Full story available on Benzinga.com
Aker : Second-Quarter and Half-Year Results 2020 | MarketScreener
2Q 2020 Financial Highlights Revenue NOK 5.4 billion EBITDA NOK 232 million EBITDA ex. special… | July 15, 2020
Aker : Awarded Letter of Intent for Askeladd Vest | MarketScreener
The development of Askeladd Vest is phase two of the multi-phased Snøhvit gas development in the Barents Sea. 'We are pleased to extend the series of… | June 30, 2020
Aker ASA: Joint Venture with Ocean Yield | MarketScreener
Aker has entered into an agreement with Ocean Yield whereby Aker will acquire from Ocean Yield 50% of seven tankers with long-term charters. The Joint Venture will own four LR2… | June 11, 2020
Microcap Akers Biosciences Spikes on Covid-Vaccine Progress
Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information…
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information…
Here's How Akers Biosciences and Premas Biotech Plan To Knock Out COVID-19 Virus; Company Halfway Through Four Milestone Plan
New York, New York--(Newsfile Corp. - April 24, 2020) - Akers Biosciences (NasdaqCM: AKER) announced a licensing agreement with Premas Biotech to find an effective vaccine for COVID-19. Premas Biotech has over 125 employees and has delivered over 650 proteins and has completed over 240 separate projects
Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate
Akers Biosciences Inc (NASDAQ: AKER ), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program. The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens — … Full story available on Benzinga.com
Akers Biosciences (AKER) stock is dropping like a stone, but for how much longer?
Akers Biosciences (AKER) shares are trading at 0.27. The company lost more than 70% of its market cap value since late March. What's driving Akers' stock price? What do investors speculate about the price of AKER shares?
Akers Biosciences (AKER): Much Upside?
Akers Biosciences (NASDAQ: AKER) shares have fallen 2% today. What is the AKER stock price forecast?
Akers Biosciences (AKER): Where Is The Stock Going?
Over the last 3 months, Aker’s stock price appreciated around 6x. What is the AKER stock price forecast?
Follow Us